Genomic polymorphisms participating in nucleotide excision repair pathways, such as excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) and xeroderma pigmentosum group D (XPD, also known as ERCC2), and the glutathione-S-transferase family of isozymes in detoxification pathways are considered potential predictors of clinical outcomes in patients given L-OHP-based chemotherapy [6-9]. Here, ERCC2 is linked to xeroderma pigmentosum group D.